C4 Therapeutics Reports Strong Q4 Results, Extends Cash Runway to 2028, and Advances Lead Clinical Programs

summarizeSummary

C4 Therapeutics announced strong fourth-quarter and full-year 2025 financial results, significantly extending its cash runway to the end of 2028, and reported key clinical advancements for its lead multiple myeloma program, cemsidomide.

check_boxKey Events

• Extended Cash Runway

  Cash, cash equivalents, and marketable securities reached $297.1 million as of December 31, 2025, enabling the company to fund its operating plan to the end of 2028.

• Lead Program Advancement

  The first patient was dosed in the Phase 2 MOMENTUM trial for cemsidomide in multiple myeloma, designed for potential accelerated approval, with enrollment expected to complete in Q1 2027.

• Strategic Collaboration

  C4 Therapeutics entered a clinical trial collaboration with Pfizer for a Phase 1b trial of cemsidomide in combination with elranatamab, expected to initiate in Q2 2026.

• Partnership Milestone Achieved

  The company earned a $2 million milestone payment from Biogen as BIIB145, a C4T-designed BTK degrader, entered clinical development.

auto_awesomeAnalysis

This 8-K filing, reporting Q4 and full-year 2025 financial results, provides a highly positive update for C4 Therapeutics. The most impactful news is the extension of the company's cash runway to the end of 2028, largely due to a successful October equity offering. This significantly de-risks the company's operations and provides ample time to achieve critical clinical milestones. Furthermore, the initiation of the Phase 2 MOMENTUM trial for cemsidomide, with potential for accelerated approval, and a new clinical collaboration with Pfizer, demonstrate strong progress in its lead multiple myeloma program. The $2 million milestone payment from Biogen also highlights successful partnership execution. These developments collectively strengthen the company's financial stability and clinical pipeline, supporting its long-term strategic roadmap.